Company Description

Exxel Pharma Inc. is a biopharmaceutical company focused on developing novel therapeutics for the treatment of neuronal hypersensitivity disorders.

We are developing EX937, our lead product candidate, for refractory chronic cough (RCC) and other hypersensitivity disorders that share the pathophysiology of hypersensitized sensory neurons.

Investigational New Drug enabling studies supporting our early clinical development program (ERCP) have been completed and we target the first-in-human (FIH) dosing in 2026, pending capitalization and completion of drug product manufacturing.

Exxel Pharma plans to execute the ERCP in Australia, primarily for two reasons, their decentralized regulatory system, which makes early clinical development very effective, and the compelling financial incentives that exist for early clinical development.